Skip to content
Get Claritide

The Short Pulse

CJC-1295 (no DAC)

Also known as Mod GRF 1-29 · CJC-1295 without DAC

Summary coverage

At a glance

What it is
A GHRH analog used to produce short GH pulses, usually paired with a GHRP.
Evidence
Small human studiesHow the tiers workClinical studies demonstrated sustained GH and IGF-1 elevation with dose-dependent responses (Teichman 2006), but there are no large-scale trials of the CJC-1295/ipamorelin combination. Why this tier
Half-life
Not established in available literature
Routes
Subcutaneous
Category
Growth hormone
FDA
Nomination withdrawn
As of 3 August 2026. What that means
WADA
Prohibited (S2.2.4)

Putting CJC-1295 (no DAC) on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.

Evidence

Why this tier

Clinical studies demonstrated sustained GH and IGF-1 elevation with dose-dependent responses (Teichman 2006), but there are no large-scale trials of the CJC-1295/ipamorelin combination. The rationale for the stack is pharmacologic rather than trial-proven.

Overview

What it is

CJC-1295 is a synthetic GHRH analog, the same class as tesamorelin, with a different molecular structure. The no-DAC version, also called Mod GRF 1-29, produces GH pulses lasting 30–60 minutes rather than the sustained elevation of the DAC version. It is designed to be combined with a growth hormone-releasing peptide such as ipamorelin.

Mechanism

How it works

CJC-1295 binds the same GHRH receptors on the anterior pituitary that tesamorelin does, but with different pharmacokinetics. Without the Drug Affinity Complex, its action is short, a GH pulse of roughly 30 to 60 minutes rather than a prolonged elevation. That short window is deliberate: it is meant to be paired with a ghrelin-receptor agonist that suppresses somatostatin, so one compound presses the accelerator while the other releases the brake.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.
  • Standard100 mcg

    1–3 times daily · Empty stomach, most commonly at bedtime

    Typically paired with ipamorelin 100–200 mcg in the same injection window. This is the no-DAC (modified GRF 1-29) figure; the DAC form is dosed weekly and far higher, and our record does not yet separate the two.

Cycle guidance
8–12 weeks on, 4 weeks off. Some protocols run continuously with monitoring.
Goals
Muscle, Sleep, Recovery, Longevity
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
Nomination withdrawnas of 3 August 2026 · US

FDA 503A bulks · nomination withdrawn

Off Category 2 and not on the 503A bulks list: limbo, not permission. The Banned Substances Control Group describes CJC-1295 as continuing to be classified as a developmental drug with no approved medical use.

Last change · Nomination withdrawn in the September 2024 tranche; the exact date is not verified in our sources.

Primary source
Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
Prohibited (S2.2.4)

Named on the 2026 List under S2.2.4, GHRH analogues. Prohibited at all times.

Reconstitution

Mixing recipes our sources document

Concentration (mg/mL) = vial mg ÷ diluent mL. On a U-100 barrel, 1 unit = 0.01 mL.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.
  1. 1
    Early weeks

    Sleep improvement is the most consistently reported first benefit of the CJC-1295/ipamorelin stack in our sources.

  2. 2
    Week 8–12

    The standard cycle length at which our sources describe reassessment for body composition and recovery.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Uncommon

  • HeadacheMild, typically early in use.
  • Flushing or warmthOccasionally after injection.
  • Injection site irritationMild.
  • Water retentionMild, usually transient.
Safety

Contraindications and interactions

Do not use if

  • Active cancer: GH promotes cell proliferation
  • Do not combine with tesamorelin, exogenous GH or other GH secretagogues without medical guidance
  • Pregnancy or nursing: no safety data in our sources

Interactions

  • Other GH secretagogues and exogenous GHavoid

    Cumulative GH-axis load with unpredictable hormonal effects.

  • Cancer therapiesavoid

    Growth-promoting pathways.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
Lyophilized powder: refrigerator 2–8°C, freezer −20°C for long-term storage. Reconstituted with bacteriostatic water: refrigerate and discard after 28 days.
Cost
Not established in available literature
Combinations

Stacks with

Only pairings our own material actually documents. Stacking is the least evidence-based part of this field.
IpamorelinThe Clean Pulse

Curated stacks including it

Deep dive

CJC-1295 (no DAC) in full

Limited coverage

Our published material covers CJC-1295 in comparison context rather than as a dedicated guide. What follows is what our sources actually state; anything they do not state is left blank rather than filled in.

What it is

A synthetic GHRH analog in the same class as tesamorelin but structurally different. "Without DAC" refers to the absence of the Drug Affinity Complex, the modification that makes the other version long-acting. The no-DAC form, also sold as Mod GRF 1-29, produces GH pulses lasting 30 to 60 minutes rather than a sustained elevation.

Why it is almost always stacked

CJC-1295 is designed as half of a pair. It binds GHRH receptors and tells the pituitary to release growth hormone. Ipamorelin, a ghrelin receptor agonist, works on an entirely different receptor and suppresses somatostatin, the hormone that brakes GH release. One presses the accelerator, the other lifts the brake, and the combined pulse is larger than either produces alone.

Our comparison page positions this stack as the popular choice for general anti-aging: sleep, recovery, skin quality, energy. Tesamorelin is the choice when visceral fat specifically is the target.

What our sources give as dosing

100 mcg per injection, one to three times daily, on an empty stomach, most commonly at bedtime; typically alongside ipamorelin at 100–200 mcg. Cycles of 8–12 weeks on and 4 weeks off, with some protocols running continuously under monitoring.

Evidence

Teichman et al. (2006) demonstrated sustained GH and IGF-1 elevation with dose-dependent responses. There are no large-scale trials of the combination. The argument for the stack is pharmacologic logic, widely used in clinical peptide practice, not trial data.

The cautions our sources raise

Active cancer is a contraindication for any GH secretagogue. The Playbook's explicit warning applies here: do not combine multiple GH-modulating peptides without medical guidance, because the hormonal effects are unpredictable. Side effects reported are mild: headache, occasional flushing, mild water retention, injection site irritation. Ipamorelin's selectivity means no cortisol or prolactin increase and no appetite stimulation.

References

Sources

  1. 1
    Teichman et al., 2006 · Prolonged stimulation of GH and IGF-I secretion by CJC-1295, JCEM 91(3)

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.